Articles les plus consultés

  • Les futures sur cac belle glissade < vix pas bon + 3%
        francis 13 Version sans publicité Marchés   Actualités   Analyses   Crypto   Fonds   Graphiques   Technique   Brokers   Outils   Portefe...
  • Nouvelles applications de médicaments avec des documents de soutien
    6% Hydroxyethyl Starch 130 / 0.4 in 0.9% Injection de chlorure de sodium (Voluven 500 mL freeflex flexible en plastique intraveineuse solut...
  • pre-market
    Top Gaining Stocks % Chg Dernier Symb Compagnie Le volume 16,22% 2.15 SRNE Sorrento Therapeut 7030 10,92% 2,64 CIE Cobalt Inte...
  • pre-market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Iridium   14.95 + 39.07% 0,60K Mondialisation de l'Inde.   0,4800 + 18,52% 1,80K...
  • pre-market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Oracle Corporation   51.30 + 10,73% 58.90K Staples Inc   9.25 + 6,81% 12,31K Delcat...
  • pre_market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Delcath   0.1230 + 24,24% 196,67K Neos Therapeutics I.   10.50 +16.67% 34.36K Enpha...
  • les élus
    Citoyens_Français ‏   @citoyenneFrance     8 juin Plus Attali : « Les élus n’ont plus de pouvoir et voici votre avenir » - Effr......
  • pre-market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Lipocine In   5.32 + 32,34% 38.64K Enphase Energy Inc   0,938 + 17,57% 10,37K Delca...
  • bonjour.. approbations
    28 juin 2017 Nom du médicament et  numéro de demande Ingrédient actif Formulaire de posologie / itinéraire Soumission Compagnie ...
  • $ pré-market
    Plus fortes hausses en préouverture Nom Dernier Var.% Vol. DragonWave Inc   1,3900 +25,23% 3,55K Alibaba   139,95 +11,35% 1,40M MoSys...

mardi 3 avril 2018

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON) | Business Wire

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON) | Business Wire: Regulatory News: GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering
Posted by at Aucun commentaire:

CURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of Year

CURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of Year
Posted by at Aucun commentaire:

Shire plc : Director/PDMR Shareholding

Shire plc : Director/PDMR Shareholding
Posted by at Aucun commentaire:

ProBiora Health Partners with The Jackson Galaxy Project to Support Oral Health in Sheltered Dogs and Cats | Business Wire

ProBiora Health Partners with The Jackson Galaxy Project to Support Oral Health in Sheltered Dogs and Cats | Business Wire: In partnership with The Jackson Galaxy Project, an acclaimed animal welfare program of GreaterGood.org, ProBiora Health has donated more than 3,000 un
Posted by at Aucun commentaire:

INTEGRA – a driving force in pipetting innovation

INTEGRA – a driving force in pipetting innovation
Posted by at Aucun commentaire:

Positive Topline Results From Phase 3 ATTR-ACT Study of Tafamidis in Patients With Transthyretin Cardiomyopathy

Positive Topline Results From Phase 3 ATTR-ACT Study of Tafamidis in Patients With Transthyretin Cardiomyopathy
Posted by at Aucun commentaire:

Humans survived abrupt climate change 11,000 years ago - Global Times

Humans survived abrupt climate change 11,000 years ago - Global Times
Posted by at Aucun commentaire:
Inscription à : Articles (Atom)